Evidence map›Paper›PMID 39503175›Full record

ArticlePediatric pulmonology2025

Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study.

Yali Zeng, Zhifeng Huang, Yanqiong Wang, Binchun Lin, Depeng Zhao, Chuanzhong Yang, Xueyu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. [Advances in clinical pharmacotherapy for neonatalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yali ZengDepartment of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
Zhifeng HuangDepartment of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
Yanqiong WangDepartment of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
Binchun LinDepartment of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
Depeng ZhaoDepartment of Reproductive Medicine, Shenzhen maternity and child healthcare hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
Chuanzhong YangDepartment of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.
Xueyu ChenDepartment of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, the First School of Medicine, Southern Medical University, Shenzhen, China.ORCID http://orcid.org/0000-0002-7066-0501

Funding

This study is supported by National Natural Science Foundation of China (82101803 to XC and 82371707 to CY), Sanming Project of Medicine in Shenzhen (SZSM202211001), Shenzhen Science and Technology Program (JCYJ20210324131200002 to DZ) and Shenzhen Key Laboratory of Maternal and Child Health and Diseases (ZDSYS20230626091559006).
6 · The paper itself

Abstract

objectivesTo test the effect of azithromycin in reducing bronchopulmonary dysplasia (BPD) risk in extremely preterm infants (EPI) without pulmonary infection. STUDY

designA retrospective cohort study was performed in EPI in a tertiary unit from September 2018 to September 2022. Since only Ureaplasma species positive infants were treated with azithromycin, we included infants without Ureaplasma species (no azithromycin treatment) and those diagnosed with Ureaplasma species colonization (azithromycin treatment) in the study, while infants with Ureaplasma species pneumonia were excluded. The primary outcome was grade II

resultsA total of 237 EPIs were included in the current study, of which 202 infants were classified as no azithromycin treatment (Ureaplasma species negative) and 35 infants were classified as azithromycin treatment (Ureaplasma species colonization). Clinical characteristics were similar between groups. Infants treated with azithromycin had a significantly lower rate of grade II

conclusionAzithromycin is associated with a reduced risk of grade II

Indexed as

Anti-Bacterial AgentsAzithromycinBronchopulmonary DysplasiaCohort StudiesFemaleHumansInfant, Extremely PrematureInfant, NewbornMaleRetrospective StudiesUreaplasmaUreaplasma InfectionsAnti-Bacterial AgentsAzithromycininflammationlungnewbornUreaplasma

Identifiers

PMID39503175
PMCPMC11758769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.